Public omics datasets from sequencing and array-based platforms now amount to millions of samples across thousands of studies and projects. This wealth of data is difficult to access and analyze due to heterogeneous and incomplete metadata, varying assay quality, and limited amounts of raw data provided for certain platforms. Despite this, accessing and reusing public omics data is an economical and prudent means of planning and conducting new experiments.